PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2268 participants.
Also called NCT05709626
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,268 participants
- Sponsor
- Registry
-
NCT05709626
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT05709626. Randomized; no masking; primary purpose treatment. Start 2023-04-07 (actual); primary completion 2026-02-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction
- Acronym
- PREMIUM
- Condition
- ST-segment Elevation Myocardial Infarction (STEMI)
- Intervention (Drug)
- No aspirin (Prasugurel monotherapy)
- Intervention (Drug)
- 12-month DAPT
- Lead sponsor
- Kindai University
- Collaborator
- Boston Scientific Corporation
Record details
- Record id
cardio:ct-nct05709626- Content hash
ad4f335de7285eb81784be1b666d49e44e9681b0facb33fa8fe6c025cbce9eb6